Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Natural Fruit, Vegetable Compound Blocks Alzheimer’s Disease in Mice

By BiotechDaily International staff writers
Posted on 04 Feb 2014
A compound that is found in fruits and vegetables, from strawberries to cucumbers, has been shown to halt memory loss that accompanies Alzheimer’s disease (AD) in mice. In research on mice engineered to develop AD symptoms less than one year after birth, a daily dose of the substance, a flavonol called fisetin, prevented the progressive memory and learning impairments associated with AD.

The agent, however, did not alter the formation of amyloid plaques in the brain, accumulations of proteins that are typically the culprit for AD development. The new finding suggests a way to treat AD symptoms independently of targeting amyloid plaques.

“We had already shown that in normal animals, fisetin can improve memory,” said Dr. Pamela Maher, a senior staff scientist in the Salk Institute for Biological Studies’ (La Jolla, CA, USA) cellular neurobiology laboratory who led the new study. “What we showed here is that it also can have an effect on animals prone to Alzheimer’s.”

Dr. Maher, more than 10 years ago, discovered that fisetin helps protect neurons in the brain from the effects of aging. She and her colleagues have since, in both isolated cell cultures and mouse studies, investigated how the substance has both antioxidant and anti-inflammatory effects on cells in the brain. Most recently, they discovered that fisetin activates a cellular pathway known to be involved in memory. “What we realized is that fisetin has a number of properties that we thought might be beneficial when it comes to Alzheimer’s,” said Dr. Maher.

Therefore, the scientists looked to a strain of mice that have mutations in two genes associated with AD. The researchers took a subset of these mice and, when they were only three months old, started to add fisetin to their food. The researchers, as the mice got older, tested their learning skills and memory with water mazes. By nine months of age, mice that had not received fisetin began performing more poorly in the mazes. Mice that had received a daily dose of the compound, however, performed as well as normal mice, at both nine months and one-year-old. “Even as the disease would have been progressing, the fisetin was able to continue preventing symptoms,” Dr. Maher commented.

In collaboration with scientists from the University of California, San Diego (USA), the scientists then examined the levels of different molecules in the brains of mice that had received doses of fisetin and those that had not. In mice with Alzheimer’s symptoms, they found, pathways involved in cellular inflammation were activated. In the animals that had taken fisetin, those pathways were dampened and anti-inflammatory molecules were present instead. One protein in particular, known as p35, was blocked from being cleaved into a shorter version when fisetin was taken. The shortened version of p35 is known to switch on and off many other molecular pathways. The study’s findings were published December 17, 2013, in the journal Aging Cell.

Studies on isolated tissue had hinted that fisetin might also decrease the number of amyloid plaques in AD affected brains. However, that observation was not evidenced in the mice studies. “Fisetin didn’t affect the plaques,” said Dr. Maher. “It seems to act on other pathways that haven't been seriously investigated in the past as therapeutic targets.”

Next, Dr. Maher’s team hopes to understand more of the molecular details on how fisetin affects memory, including whether there are targets other than p35. “It may be that compounds like this that have more than one target are most effective at treating Alzheimer’s disease,” stated Dr. Maher, “because it’s a complex disease where there are a lot of things going wrong.”

The scientists also aim to develop new studies to look at how the timing of fisetin doses affect its influence on Alzheimer’s. “The model that we used here was a preventive model,” explained Maher. “We started the mice on the drugs before they had any memory loss. But obviously human patients don’t go to the doctor until they are already having memory problems.”

The next phase of the research, therefore, in moving the discovery toward the clinic, according to the researchers, is to assess whether fisetin can reverse declines in memory once the processes have already started.

Related Links:

Salk Institute for Biological Studies
University of California, San Diego



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.